Search results
Found 52 matches for
Pending final negotiations, the grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancer. The competitive funding award highlights Theolytics’ innovative science and strong clinical development plan. The application is coordinated with several major international clinical centres and world-class partners.
Let’s just get married – the story of an acquisition
5 March 2026
"We decided to skip the engagement and just get married" – that’s how Hutano Diagnostics’ CEO Atherton Mutombwera describes his company’s acquisition by EDx Medical in 2023. The meeting of minds between him and the purchaser’s CEO, Dr Mike Hudson, was the culmination of six years of hard work by Atherton developing multiplex lateral flow diagnostics based on aptamers.
Highlighting our award-winning apprentices in NAW 2026
16 February 2026
Apprentices are a vital part of BioEscalator life, and we always enjoy celebrating their achievements and impact in National Apprenticeship Week.
AstraZeneca Exchange launches in Oxford with support for BioEscalator tenants
3 February 2026
What started out as an initiative to embed AstraZeneca into Cambridge's ecosystem has turned into a Science and Business Mentoring programme, AstraZeneca Exchange, which has now been launched at the University of Oxford. So far four BioEscalator tenants who will benefit from this valuable scheme have been named - Infinitopes, Spectre Bio, Granza Bio and ISOgenix Limited.
First Cambridge – Oxford BioVenture Showcase proves a success
22 January 2026
The positive feedback from investors and presenting companies at our recent first Cambridge – Oxford BioVenture Showcase with the Milner Therapeutics Institute shows what a success it was. We will certainly be doing it again!
Oxford Cancer Analytics graduates from the BioEscalator
15 December 2025
In 2022, Oxford Cancer Analytics was voted the company Most Likely to be a Unicorn at that year’s BioEscalator Pitch Battle. Fast forward three years, and the company is well along its growth trajectory. OXcan has graduated from our facility as a fast-scaling diagnostics company, leveraging advanced proteomics and machine learning to develop innovative tests for earlier and more accurate assessment of lung diseases.
Akimbo Bio crosses the bridge from academia to industry as it joins the BioEscalator
3 December 2025
The BioEscalator is pleased to welcome Akimbo Bio to its community of innovative bioscience start-ups. Co-founded by two Oxford researchers, the company is developing a next-generation immunotherapy platform that leverages intelligent receptor crosstalk to enhance both the efficacy and safety of cancer treatments.
Spectre Bio moves from computation to the lab as it joins the BioEscalator
3 December 2025
The BioEscalator is delighted to welcome Spectre Bio to its start-up community. The company joins us as it transitions from computational research to laboratory-based development, bringing an exciting new immunomodulatory platform to the BioEscalator ecosystem.
Exogene Graduates from the BioEscalator
15 October 2025
We are delighted to celebrate the graduation of Exogene as it transitions from the BioEscalator to its new home at the Wood Centre for Innovation.
Professor Heidi Johansen-Berg joins the BioEscalator Management Board
8 October 2025
We are delighted to welcome Professor Heidi Johansen-Berg to our Management Board, an expert in brain imaging and neuroplasticity, and a champion of innovation in the life sciences.
Omos Biosciences joins the BioEscalator community to tackle cancer earlier
9 September 2025
We are delighted to welcome Omos Biosciences as the newest member of the BioEscalator community. The company has ambitious plans to transform cancer prevention by intervening at the pre-cancerous stage.
An insight into our sixth annual Pitch Battle - with competition as intense as ever!
30 July 2025
It was an afternoon of high drama as BioEscalator tenants took to the floor in our recent annual Pitch Battle to compete for the Best Pitch prize, sponsored by Oxford North, and a range of other accolades.
Business Apprentice Becson joins the BioEscalator
23 July 2025
Who knew? Young adults do listen to their parents, and the BioEscalator is very glad about that. Becson Ody, our first Business Administration & Reception apprentice, found out about apprenticeships through his father, who is a ‘big advocate’.
Welcome, Sandbox Bioscience, to the BioEscalator Community!
22 May 2025
We are excited to announce that Sandbox Bioscience, an ambitious biotech start-up founded by a team of virology experts from the Oxford ecosystem, has joined the BioEscalator.
The Gender Advantage: Building Inclusive and Thriving Ventures
20 March 2025
To celebrate International Women's Day 2025, the BioEscalator was delighted to host a double panel discussion and networking event with EnSpire Oxford and Advanced Oxford.
Leading academics and innovators join refreshed BioEscalator Management Board
30 October 2024
In its first major refresh since its establishment in 2018, the BioEscalator is delighted to welcome five leading University of Oxford academics and innovators to its Management Board. Professors Catherine Green OBE, Beth Psaila, Molly Stevens DBE, Krina Zondervan and Peter Callow, Financial Controller of the Medical Sciences Division at the University of Oxford. The Management Board provides a source of expertise for BioEscalator tenants and works to enhance research at the University by building strong links with small life sciences companies.
Eterna Biologics: Revolutionising RNA therapeutics
28 August 2024
We are excited to welcome Eterna Biologics, a University of Oxford biotech spinout company with a mission to unleash the full potential of RNA medicines. The company aims to enhance global health by expanding the applicability of RNA-targeting medicine to develop treatment for a wide range of human conditions.
U-Ploid thrilled to join the BioEscalator Community
21 August 2024
U-Ploid Biotechnologies joins the BioEscalator to develop groundbreaking therapeutics that improve egg quality and revolutionise IVF.
RE-AIM Therapeutics: Targeting disease causal cells to cure autoimmunity
18 July 2024
We are delighted to welcome RE-AIM Therapeutics to the BioEscalator community, a start-up focused on developing antibody-based curative therapies for inflammatory disorders, such as psoriasis and inflammatory bowel disease.
The BioEscalator welcomes SiGenex to its growing community
18 July 2024
SiGenex is advancing genomic medicine with its innovative, artificial intelligence-powered in-hospital sequencing platform. The company's technology is designed to transform how hospitals, clinics, and medical centres perform targeted next-generation sequencing (NGS) tests.
Bioarchitech graduates from the BioEscalator: A new chapter for innovative cancer therapy
17 July 2024
Bioarchitech's departure from the BioEscalator marks the beginning of an exciting new phase for the pioneering cancer therapy company, as it transitions to the next stage of its innovative journey.